fuzzyjr, while am excited by the science I do agree with you.
There is a huge gap in translating the great science into something that investors can get excited about. Then there is another gap in terms of getting that great information out the right audiences including the financial press. Then of course there is the lack of a NASDAQ listing.
What is difficult to judge is where rvx-208 (apabetalone) sits in the minds of the scientific communities. We generally don't have any information on how all of these presentations to science audiences are received and we don't know what the pharma industry is thinking about it other than no BP has ponied up big to take a shot at RVX.
There might be some hope in success of tangible and valuable achievements such as;
- Success in the orphan trial (PNH) (could have a huge impact on share price on it's own and be a separate entity to sell).
- Moving past the "futility analysis" for BETonMACE in 2017...again another key event.
- The next regional deal. We do know that a pending deal with Hepalink drove the share price over $3.00. Rumours preceeding the next deal may have an impact.
- Success of the current zen3694 trial on castration resistant metastatic prostate cancer may well have a halo effect on apabtalone and BET inhibition sciience overall.
There is certainly a huge gap between the current RVX share price and where it should be with a drug (apabetalone) in the phase 3 BETonMACE clinical trial with a steering committee made up of some the top scientists in the world.
We do know that there is no demand for this stock and we do know that there is NO effective brand positioning and no effective marketing plan for the RVX brand. My sense is that RVX does not understand this and they don't care. I feel they have the time and money to wait for the blockbuster and so marketing is irrelevant.
So it is an excellent time to accumulate. IMHO
Cheers
Toinv
